Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.69 |
| ▸ | BRAF | P15056 | 2/20 | 0.69 |
| ▸ | FLT4 | P35916 | 2/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.69 |
| ▸ | CIT | O14578 | 1/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.69 |
| ▸ | STK17B | O94768 | 1/20 | 0.69 |
| ▸ | STK10 | O94804 | 1/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.69 |
| ▸ | ABL1 | P00519 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29430978 | 1.00 | EGFR (0.69) | EGFRERBB2BRAFFLT4KDR | |
| SCHEMBL7622647 | 0.89 | EGFR (0.57) | EGFRERBB2BRAFFLT4KDR | |
| SCHEMBL28820784 | 0.87 | EGFR (0.70) | EGFRERBB2BRAFFLT4KDR | |
| SCHEMBL29882073 | 0.87 | EGFR (0.70) | EGFRERBB2BRAFFLT4KDR | |
| SCHEMBL3568126 | 0.85 | EGFR (0.69) | EGFRERBB2BRAFFLT4KDR | |
| SCHEMBL3520111 | 0.82 | EGFR (0.72) | EGFRERBB2KDRCITGAK | |
| Gefitinib SCHEMBL29351336 | 0.82 | EGFR (1.00) | EGFRERBB2BRAFFLT4KDR | |
| SCHEMBL12308286 | 0.82 | EGFR (0.77) | EGFRERBB2BRAFFLT4KDR | |
| Gefitinib SCHEMBL29351046 | 0.82 | EGFR (1.00) | EGFRERBB2BRAFFLT4KDR | |
| Gefitinib SCHEMBL465143 | 0.82 | EGFR (1.00) | EGFRERBB2BRAFFLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612077-B2 | Crystalline forms of the anti-cancer compound ZD1839 | ASTRAZENECA AB (SE) | 2009-11-03 | — | — | US | disclosed |
| EP-1546119-B1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | EP | disclosed |
| US-20050209229-A1 | Form 3 ZD1839 dimethylsulfoxide solvate; ZD1839 is known as the tradename Iressa and as gefitinib | ASTRAZENECA AB (SE) | 2005-09-22 | — | — | US | disclosed |
| EP-1546119-A1 | PROCESS FOR THE PREPARATION OF 4- (3'CHLORO-4'-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | AstraZeneca AB (SE) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004024703-A1 | PROCESS FOR THE PREPARATION OF 4- (3’-CHLORO-4’-FLUOROANILINO) -7-METHOXY-6- (3-MORPHOLINOPROPOXY) QUINAZOLINE | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209229-A1 | Form 3 ZD1839 dimethylsulfoxide solvate; ZD1839 is known as the tradename Iressa and as gefitinib | KRAS, IWS1, JAK2 | EGFR 14/4885ERBB2 597/4885BRAF 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.